Literature DB >> 35732996

Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model.

Tam Nguyen-Hoai1, Oliver Hohn2, Antonio Pezzutto3, Jörg Westermann4.   

Abstract

Genetic vaccination using naked plasmid DNA is an immunization strategy both against infectious diseases and cancer.In order to improve efficacy of DNA vaccines, particularly in large animals and humans, different strategies have been pursued. These vaccination strategies are based on different application routes, schedules and coexpression of immunomodulatory molecules as adjuvants. Our mouse tumor model offers the possibility to investigate Her2/neu DNA vaccines in different settings, that is, intramuscular or intradermal application with or without coexpression of adjuvants. The immunogenicity of predicted peptides for Her2/neu specific memory T cells were screened and confirmed after intramuscular and intradermal application. Protection from tumor growth in tumor challenge experiments and both T cell and humoral immune responses against Her2/neu peptides are used as surrogate parameters for vaccine efficacy.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  DNA vaccination; Gene gun immunization; Her2/neu-specific immune responses; Her2/neu + mouse tumor model

Mesh:

Substances:

Year:  2022        PMID: 35732996     DOI: 10.1007/978-1-0716-2441-8_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Induction and measurement of cytotoxic T lymphocyte activity.

Authors:  John Wonderlich; Gene Shearer; Alexandra Livingstone; Andrew Brooks
Journal:  Curr Protoc Immunol       Date:  2006-05

2.  Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma.

Authors:  Wolfgang Walther; Ulrike Stein; Iduna Fichtner; Dennis Kobelt; Jutta Aumann; Franziska Arlt; Peter M Schlag
Journal:  Mol Ther       Date:  2005-10-03       Impact factor: 11.454

3.  Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.

Authors:  Y Nagata; R Furugen; A Hiasa; H Ikeda; N Ohta; K Furukawa; H Nakamura; K Furukawa; T Kanematsu; H Shiku
Journal:  J Immunol       Date:  1997-08-01       Impact factor: 5.422

4.  Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Authors:  Håkan Norell; Isabel Poschke; Jehad Charo; Wei Z Wei; Courtney Erskine; Marie P Piechocki; Keith L Knutson; Jonas Bergh; Elisabet Lidbrink; Rolf Kiessling
Journal:  J Transl Med       Date:  2010-06-07       Impact factor: 5.531

Review 5.  Clinical studies of vaccines targeting breast cancer.

Authors:  Byung K Ko; Kouichiro Kawano; James L Murray; Mary L Disis; Clay L Efferson; Henry M Kuerer; George E Peoples; Constantin G Ioannides
Journal:  Clin Cancer Res       Date:  2003-08-15       Impact factor: 12.531

Review 6.  A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.

Authors:  Omna Sharma; Ali A Sultan; Hong Ding; Chris R Triggle
Journal:  Front Immunol       Date:  2020-10-14       Impact factor: 7.561

Review 7.  Cancer Vaccines, Adjuvants, and Delivery Systems.

Authors:  Samantha J Paston; Victoria A Brentville; Peter Symonds; Lindy G Durrant
Journal:  Front Immunol       Date:  2021-03-30       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.